2023 Fiscal Year Final Research Report
Synergistic effect of anti-claudin-4 antibody on chemotherapy for oral cancer
| Project/Area Number |
21K10143
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 57060:Surgical dentistry-related
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
國安 弘基 奈良県立医科大学, 医学部, 教授 (00253055)
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | 抗claudin-4抗体 / 口腔がん / 化学療法 |
|---|
| Outline of Final Research Achievements |
Anti-claudin-4 antibody dose-dependently inhibits growth and invasion of oral squamous cell carcinoma line and promotes apoptosis. In sphere analysis, anti-claudin-4 antibody also shows inhibitory effect on stemness. Furthermore, anti-claudin-4 antibody shows synergistic effect on 5-FU and cetuximab. Claudin-4 strongly expressed in advanced oral cancer, and therefore synergistic antitumor effect is expected by combination of anti-claudin-4 antibody with anti-cancer drugs.
|
| Free Research Field |
口腔外科学
|
| Academic Significance and Societal Importance of the Research Achievements |
抗claudin-4 抗体を用いることにより口腔癌に対する既存の化学療法の効果の増強が期待できる。
|
